slides · global inventory
List
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,471
Current window 90,361-90,390
Pages 3,683
Rows per page 30
Component
90,361-90,390 of 110,471
04
Includes a footnote regarding a 1-for-25 reverse stock split.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
05
The slide uses a pipeline chart format to show the development status of seven different programs.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
09
The slide uses a numbered list format to present strategic pillars.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)1 hit
16
The chart uses a vertical axis to imply a safety spectrum (Safest to Riskiest) and a horizontal axis for efficacy (clinical remission %).Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Aha Moment1 hit
19
Includes structural visualization of the epitope and two dose-response curves.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Aha Moment1 hit
20
The chart shows dose-response curves for three donors; the table summarizes the calculated EC50 values.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
21
The chart uses a log-linear scale for concentration over time to demonstrate the beta-elimination phase.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
22
The slide uses a bar chart to compare pharmacokinetic properties between a proprietary drug candidate (SPY001) and a competitor (Entyvio).Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
24
The slide uses a bar chart to show benchmark data alongside a specific exposure-response analysis for vedolizumab.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
25
Data from GEMINI 1 study; highlights that higher exposure does not necessarily correlate with higher remission rates.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
30
Slide 29 from a UBS presentation. Includes pro forma data for combined UBS and Credit Suisse entities.UBS | Fixed Income Presentation Deck | 44 slides · UBS
Conference presentation Investor relations Beat · Action1 hit
37
The slide details RWA and LRD percentages for various capital buffers and requirements.UBS | Fixed Income Presentation Deck | 44 slides · UBS
Conference presentation Investor relations Beat · Action1 hit
43
UBS | Fixed Income Presentation Deck | 44 slidesUBS | Fixed Income Presentation Deck | 44 slides · UBS
Conference presentation Investor relations Beat · Action1 hit
09
The slide uses a comparison frame to contrast the negative outcomes of a standalone scenario with the positive outcomes of full integration.UBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Before After1 hit
13
The chart shows a projected decline in RWA from 55bn in 2Q23 to 28bn by YE26.UBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations Beat · Evidence & ProofLoop · Before After1 hit
25
Excludes Credit Suisse; includes YoY and QoQ growth metrics.UBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations Beat · Impact & Next StepsLoop · Maturity Curve1 hit
26
Excludes Credit Suisse; includes specific footnotes regarding gains on sale.UBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations Beat · Impact & Next StepsLoop · Maturity Curve1 hit
27
Excludes Credit Suisse. Includes specific commentary on Global Markets and Global Banking performance drivers.UBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations Beat · Solution & ApproachLoop · Maturity Curve1 hit
29
Includes a waterfall chart for pre-tax income and a summary table of revenues and expenses.UBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations Beat · Solution & Approach1 hit
30
The slide uses a waterfall bridge to explain the transition from a negative 2Q23 PBT to a projected break-even/positive state.UBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations Beat · Solution & Approach1 hit
32
UBS | Results Presentation Deck | 41 slidesUBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations Beat · Solution & Approach1 hit
37
The slide uses a waterfall chart to explain the variance between projected and actual negative goodwill for the Credit Suisse acquisition.UBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations 1 hit
38
The slide compares RWA (excl. operational risk) and LRD metrics across five asset classes: Equities, Macro, Loans, Securitized products, and Credit/HQLA.UBS | Results Presentation Deck | 41 slides · UBS
Conference presentation Investor relations 1 hit
06
The slide uses a hub-and-spoke style diagram to show the flow of value between sellers, the platform, and fans.Vivid Seats | Investor Presentation Deck | 22 slides · Vivid Seats
Pitch deck Investor relations Beat · Solution1 hit
07
The slide uses a cloud icon to represent synchronization between desktop and mobile app interfaces.Vivid Seats | Investor Presentation Deck | 22 slides · Vivid Seats
Pitch deck Investor relations Beat · Solution1 hit
10
The slide uses a split-screen layout to contrast the loyalty program (left) and gamified engagement (right).Vivid Seats | Investor Presentation Deck | 22 slides · Vivid Seats
Pitch deck Investor relations Beat · Solution1 hit
19
Uses a hub-and-spoke diagram to illustrate components of strategic flexibility.Vivid Seats | Investor Presentation Deck | 22 slides · Vivid Seats
Pitch deck Investor relations 1 hit
02
The slide features a baseball player image, likely a metaphor for 'hitting it out of the park' or performance.Vivid Seats | Results Presentation Deck | 19 slides · Vivid Seats
Conference presentation Investor relations 1 hit
05
The slide uses a process-like flow to connect GOV to Revenue to EBITDA, implying a conversion or waterfall relationship.Vivid Seats | Results Presentation Deck | 19 slides · Vivid Seats
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
11
The slide uses a hub-and-spoke diagram to illustrate how various financial components contribute to 'Strategic Flexibility'.Vivid Seats | Results Presentation Deck | 19 slides · Vivid Seats
Conference presentation Investor relations Beat · FinancialsLoop · Why Now1 hit